Navigation Links
Integrated BioPharma's Proprietary Vaccine Technology Achieves,Strong Positive Results

HILLSIDE, NJ, March 12, 2007—InB:Biotechnologies, Inc. ("BioTech"), a wholly-owned subsidiary of Integrated BioPharma, Inc. (NASDAQ: INBP), today announced strong positive results in studies of vaccines against HPV, anthrax and plague made using INBP's novel, proprietary AIPwLV™ vaccine technology. The studies were conducted by the Fraunhofer USA Center for Molecular Biotechnology (CMB), the Contract Research Organization led by Dr. Vidadi Yusibov, through which BioTech executes its vaccine-related development activities.

The results, reported in the respected peer-reviewed scientific journal Vaccine, demonstrated pre-clinical efficacy of key HPV proteins produced by the AIPwLV™ technology, which induced specific immune responses and protected against HPV challenge infection. HPV is the primary etiologic agent of cervical cancer, which represents the third leading cause of cancer-related death among women worldwide. The reported results support the possibility of producing prophylactic and therapeutic HPV vaccines using the AIPwLV™ technology.

The studies also demonstrated that other vaccine candidates made using the AIPwLV™ technology induced specific immune responses and conferred complete protection against lethal doses of anthrax and plague, two substances considered as likely bioterrorism agents.

"The AIPwLV™ technology achieves rapid, high level production of antigens, antibodies and therapeutic proteins in non-genetically modified plants utilizing a proprietary launch-vector technology," said Dr. Yusibov, the Executive Director of CMB. "It offers rapid, unparalleled scalability of vaccine production and cost efficiency, addressing the principal concerns affecting current methods of vaccine production, particularly where large scale or rapid inoculation is desired," added Dr. Yusibov.

About Integrated BioPharma, Inc. Integrated BioPharma is a unique grouping of companies presently serving the varied needs of the health care industry. Through its nutraceutical business, the Company creates, develops, manufactures and markets products worldwide. The Company’s biotechnology business uses its patented plant-based technology to produce vaccines and therapeutic antibodies. Its pharmaceutical business operates a cGMP facility for the production and sale of Paclitaxel and related drugs and provides technical services through its contract research organization. Further information is available at www.iBioPharma.com.

Statements included in this release related to Integrated BioPharma, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. Further information on potential risk factors that could affect the company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.

Contact: Jeffery Leach, VP Dina Masi, CFO Integrated BioPharma Inc 888-319-6962 d.masi@ibiopharma.com


'"/>




Related medicine technology :

1. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results
2. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
3. Neurogen Announces Positive Results for Proprietary Insomnia Drug in Two Chronic Insomnia Clinical Trials
4. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
5. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
6. Neurogen Proprietary Insomnia Compound Data for Two Studies Presented at Associated Professional Sleep Societies Annual Meeting
7. Neurogen Proprietary Insomnia Compound Data Presented at Associated Professional Sleep Societies Annual Meeting
8. Neurogen Proprietary Insomnia Compound Data Presented at American Psychiatric Association Annual Meeting
9. Cytogen Reports Publication Validating the Utility of its Proprietary ProChart Database
10. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
11. Helix BioMedix to Discuss Potential of Its Proprietary Peptides at the BIO International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... , Feb. 17, 2017  Noble Capital Markets ... ESSA Pharma Inc. (Nasdaq: EPIX ). The ... Kumar Raja , PhD. ESSA Pharmaceuticals ... castration resistant prostate cancer (CRPC). Its lead compound EPI-506, ... the amino-terminal domain of the androgen receptor, thereby has ...
(Date:2/16/2017)... 16, 2017 Research and Markets has ... Medical Device Technologies" report to their offering. ... Traditional medical ... general instruments, non-drug coated implantables, large endoscopes, needle based drug ... over the last two to three decades for the treatment ...
(Date:2/16/2017)... DaVita Inc. (NYSE: DVA ) today announced results ... Net income attributable to DaVita Inc. for the ... or $0.80 per share and $880 million, or $4.29 per ... DaVita Inc. for the quarter and year ended December 31, ... or $0.98 per share, and $789 million, or $3.85 per ...
Breaking Medicine Technology:
(Date:2/18/2017)... (PRWEB) , ... February 17, 2017 , ... ... , drvallecillos.com , Beverly Hills plastic surgeon Dr. Glenn Vallecillos ... cells. , Dr. Vallecillos says, "Traditionally, plastic surgery has been centered around that ...
(Date:2/17/2017)... , ... February 17, 2017 , ... Smiles by Seese ... Center in Davidson, NC. Dr. Brian Seese leads the practice as a skilled and ... under one roof. Smiles by Seese serves patients of all ages with excellence in ...
(Date:2/17/2017)... ... February 17, 2017 , ... For the ... management solution to the exhibit floor for the 2017 HIMSS Conference & ... From Feb. 19–23, 2017, more than 40,000 healthcare industry professionals are expected at ...
(Date:2/17/2017)... ... 2017 , ... Qualis Health, one of the nation's leading ... DecisionHealth Platinum Awards in recognition of its innovative healthcare management programs that are ... award categories, highlighting four of the organization’s current programs:, , ...
(Date:2/17/2017)... ... February 17, 2017 , ... Pharmica Consulting attended CHI's ... facets of clinical trial planning and management. Pharmica discussed the importance of effective ... addition, attendees stopping by Pharmica’s booth were able to demo its cloud-based ...
Breaking Medicine News(10 mins):